Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

HMS faculty, help us improve the algorithms in Profiles by uploading your CV!

Anat Stemmer-Rachamimov, M.D.

Co-Author

This page shows the publications co-authored by Anat Stemmer-Rachamimov and Vijaya Ramesh.
Connection Strength

1.522
  1. Expression of NF2-encoded merlin and related ERM family proteins in the human central nervous system. J Neuropathol Exp Neurol. 1997 Jun; 56(6):735-42.
    View in: PubMed
    Score: 0.173
  2. The path forward: 2015 International Children's Tumor Foundation conference on neurofibromatosis type 1, type 2, and schwannomatosis. Am J Med Genet A. 2017 Jun; 173(6):1714-1721.
    View in: PubMed
    Score: 0.171
  3. A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas. Oncotarget. 2015 Jul 10; 6(19):16981-97.
    View in: PubMed
    Score: 0.151
  4. Regulation of mTOR complex 2 signaling in neurofibromatosis 2-deficient target cell types. Mol Cancer Res. 2012 May; 10(5):649-59.
    View in: PubMed
    Score: 0.120
  5. NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. Mol Cell Biol. 2009 Aug; 29(15):4250-61.
    View in: PubMed
    Score: 0.099
  6. Phosphorylation of tuberin as a novel mechanism for somatic inactivation of the tuberous sclerosis complex proteins in brain lesions. Cancer Res. 2004 Feb 01; 64(3):812-6.
    View in: PubMed
    Score: 0.069
  7. Gene replacement therapy in a schwannoma mouse model of neurofibromatosis type 2. Mol Ther Methods Clin Dev. 2022 Sep 08; 26:169-180.
    View in: PubMed
    Score: 0.061
  8. Survey of somatic mutations in tuberous sclerosis complex (TSC) hamartomas suggests different genetic mechanisms for pathogenesis of TSC lesions. Am J Hum Genet. 2001 Sep; 69(3):493-503.
    View in: PubMed
    Score: 0.058
  9. Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK. PLoS One. 2021; 16(7):e0252048.
    View in: PubMed
    Score: 0.057
  10. Developmental expression of the tuberous sclerosis proteins tuberin and hamartin. Acta Neuropathol. 2001 Mar; 101(3):202-10.
    View in: PubMed
    Score: 0.056
  11. Gene therapy for tuberous sclerosis complex type 2 in a mouse model by delivery of AAV9 encoding a condensed form of tuberin. Sci Adv. 2021 01; 7(2).
    View in: PubMed
    Score: 0.055
  12. NHE-RF, a merlin-interacting protein, is primarily expressed in luminal epithelia, proliferative endometrium, and estrogen receptor-positive breast carcinomas. Am J Pathol. 2001 Jan; 158(1):57-62.
    View in: PubMed
    Score: 0.055
  13. Loss of the NF2 gene and merlin occur by the tumorlet stage of schwannoma development in neurofibromatosis 2. J Neuropathol Exp Neurol. 1998 Dec; 57(12):1164-7.
    View in: PubMed
    Score: 0.048
  14. The NF2 gene and merlin protein in human osteosarcomas. Neurogenetics. 1998 Dec; 2(1):73-4.
    View in: PubMed
    Score: 0.048
  15. EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma. Neuro Oncol. 2018 08 02; 20(9):1185-1196.
    View in: PubMed
    Score: 0.047
  16. Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2. PLoS One. 2018; 13(6):e0197350.
    View in: PubMed
    Score: 0.046
  17. Universal absence of merlin, but not other ERM family members, in schwannomas. Am J Pathol. 1997 Dec; 151(6):1649-54.
    View in: PubMed
    Score: 0.045
  18. A new patient-derived orthotopic malignant meningioma model treated with oncolytic herpes simplex virus. Neuro Oncol. 2016 09; 18(9):1278-87.
    View in: PubMed
    Score: 0.040
  19. Survival benefit and phenotypic improvement by hamartin gene therapy in a tuberous sclerosis mouse brain model. Neurobiol Dis. 2015 Oct; 82:22-31.
    View in: PubMed
    Score: 0.038
  20. Genomic profiling distinguishes familial multiple and sporadic multiple meningiomas. BMC Med Genomics. 2009 Jul 09; 2:42.
    View in: PubMed
    Score: 0.025
  21. Modeling NF2 with human arachnoidal and meningioma cell culture systems: NF2 silencing reflects the benign character of tumor growth. Neurobiol Dis. 2008 Feb; 29(2):278-92.
    View in: PubMed
    Score: 0.022
  22. Inactivation patterns of NF2 and DAL-1/4.1B (EPB41L3) in sporadic meningioma. Cancer Genet Cytogenet. 2005 Oct 15; 162(2):135-9.
    View in: PubMed
    Score: 0.019
  23. Sacrococcygeal chordomas in patients with tuberous sclerosis complex show somatic loss of TSC1 or TSC2. Genes Chromosomes Cancer. 2004 Sep; 41(1):80-5.
    View in: PubMed
    Score: 0.018
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.